scispace - formally typeset
Search or ask a question
Author

Henrik E. Mei

Bio: Henrik E. Mei is an academic researcher from Leibniz Association. The author has contributed to research in topics: Mass cytometry & Immune system. The author has an hindex of 32, co-authored 70 publications receiving 5115 citations. Previous affiliations of Henrik E. Mei include Humboldt State University & Stanford University.


Papers
More filters
Journal ArticleDOI
Jonas Schulte-Schrepping1, Nico Reusch1, Daniela Paclik2, Kevin Baßler1, Stephan Schlickeiser2, Bowen Zhang3, Benjamin Krämer4, Tobias Krammer, Sophia Brumhard2, Lorenzo Bonaguro1, Elena De Domenico5, Daniel Wendisch2, Martin Grasshoff3, Theodore S. Kapellos1, Michael Beckstette3, Tal Pecht1, Adem Saglam5, Oliver Dietrich, Henrik E. Mei6, Axel Schulz6, Claudia Conrad2, Désirée Kunkel2, Ehsan Vafadarnejad, Cheng-Jian Xu7, Cheng-Jian Xu3, Arik Horne1, Miriam Herbert1, Anna Drews5, Charlotte Thibeault2, Moritz Pfeiffer2, Stefan Hippenstiel2, Andreas C. Hocke2, Holger Müller-Redetzky2, Katrin-Moira Heim2, Felix Machleidt2, Alexander Uhrig2, Laure Bosquillon de Jarcy2, Linda Jürgens2, Miriam Stegemann2, Christoph R. Glösenkamp2, Hans-Dieter Volk2, Christine Goffinet2, Markus Landthaler8, Emanuel Wyler8, Philipp Georg2, Maria Schneider2, Chantip Dang-Heine2, Nick Neuwinger2, Kai Kappert2, Rudolf Tauber2, Victor M. Corman2, Jan Raabe4, Kim Melanie Kaiser4, Michael To Vinh4, Gereon Rieke4, Christian Meisel2, Thomas Ulas5, Matthias Becker5, Robert Geffers, Martin Witzenrath2, Christian Drosten2, Norbert Suttorp2, Christof von Kalle2, Florian Kurth9, Florian Kurth10, Florian Kurth2, Kristian Händler5, Joachim L. Schultze1, Joachim L. Schultze5, Anna C. Aschenbrenner7, Anna C. Aschenbrenner1, Yang Li3, Yang Li7, Jacob Nattermann4, Birgit Sawitzki2, Antoine-Emmanuel Saliba, Leif E. Sander2, Angel Angelov, Robert Bals, Alexander Bartholomäus, Anke Becker, Daniela Bezdan, Ezio Bonifacio, Peer Bork, Thomas Clavel, Maria Colomé-Tatché, Andreas Diefenbach, Alexander T. Dilthey, Nicole Fischer, Konrad U. Förstner, Julia-Stefanie Frick, Julien Gagneur, Alexander Goesmann, Torsten Hain, Michael Hummel, Stefan Janssen, Jörn Kalinowski, René Kallies, Birte Kehr, Andreas Keller, Sarah Kim-Hellmuth, Christoph Klein, Oliver Kohlbacher, Jan O. Korbel, Ingo Kurth, Kerstin U. Ludwig, Oliwia Makarewicz, Manja Marz, Alice C. McHardy, Christian Mertes, Markus M. Nöthen, Peter Nürnberg, Uwe Ohler, Stephan Ossowski, Jörg Overmann, Silke Peter, Klaus Pfeffer, Anna R. Poetsch, Alfred Pühler, Nikolaus Rajewsky, Markus Ralser, Olaf Rieß, Stephan Ripke, Ulisses Nunes da Rocha, Philip Rosenstiel, Philipp H. Schiffer, Eva-Christina Schulte, Alexander Sczyrba, Oliver Stegle, Jens Stoye, Fabian J. Theis, Janne Vehreschild, Jörg Vogel, Max von Kleist, Andreas Walker, Jörn Walter, Dagmar Wieczorek, John Ziebuhr 
17 Sep 2020-Cell
TL;DR: This study provides detailed insights into the systemic immune response to SARS-CoV-2 infection and it reveals profound alterations in the myeloid cell compartment associated with severe COVID-19.

1,042 citations

Journal ArticleDOI
Andrea Cossarizza1, Hyun-Dong Chang, Andreas Radbruch, Andreas Acs2  +459 moreInstitutions (160)
TL;DR: These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community providing the theory and key practical aspects offlow cytometry enabling immunologists to avoid the common errors that often undermine immunological data.
Abstract: These guidelines are a consensus work of a considerable number of members of the immunology and flow cytometry community. They provide the theory and key practical aspects of flow cytometry enabling immunologists to avoid the common errors that often undermine immunological data. Notably, there are comprehensive sections of all major immune cell types with helpful Tables detailing phenotypes in murine and human cells. The latest flow cytometry techniques and applications are also described, featuring examples of the data that can be generated and, importantly, how the data can be analysed. Furthermore, there are sections detailing tips, tricks and pitfalls to avoid, all written and peer-reviewed by leading experts in the field, making this an essential research companion.

698 citations

Journal ArticleDOI
Dominik Pfister1, Dominik Pfister2, Nicolás Gonzalo Núñez3, Roser Pinyol4, Olivier Govaere5, Matthias Pinter6, Marta Szydlowska2, Revant Gupta7, Mengjie Qiu8, Aleksandra Deczkowska9, Assaf Weiner9, Florian Müller2, Ankit Sinha10, Ankit Sinha11, Ekaterina Friebel3, Thomas Engleitner2, Thomas Engleitner10, Daniela Lenggenhager3, Anja Moncsek3, Danijela Heide2, Kristin Stirm2, Jan Kosla2, Eleni Kotsiliti2, Valentina Leone2, Michael Dudek10, Suhail Yousuf8, Donato Inverso12, Donato Inverso2, Indrabahadur Singh2, Ana Teijeiro, Florian Castet4, Carla Montironi4, Philipp K. Haber13, Dina Tiniakos5, Dina Tiniakos14, Pierre Bedossa5, Simon Cockell5, Ramy Younes15, Ramy Younes5, Michele Vacca16, Fabio Marra17, Jörn M. Schattenberg, Michael Allison16, Elisabetta Bugianesi15, Vlad Ratziu18, Tiziana Pressiani, Antonio D'Alessio, Nicola Personeni19, Lorenza Rimassa19, Ann K. Daly5, Bernhard Scheiner6, Katharina Pomej6, Martha M. Kirstein20, Arndt Vogel20, Markus Peck-Radosavljevic, F. Hucke, Fabian Finkelmeier, Oliver Waidmann, Jörg Trojan, Kornelius Schulze21, Henning Wege21, Sandra Koch22, Arndt Weinmann22, Marco Bueter3, Fabian Rössler3, Alexander Siebenhüner3, Sara De Dosso, Jan-Philipp Mallm2, Viktor Umansky12, Viktor Umansky2, Manfred Jugold2, Tom Luedde23, Andrea Schietinger24, Andrea Schietinger25, Peter Schirmacher8, Brinda Emu2, Hellmut G. Augustin12, Hellmut G. Augustin2, Adrian T. Billeter8, Beat P. Müller-Stich8, Hiroto Kikuchi26, Dan G. Duda26, Fabian Kütting27, Dirk Waldschmidt27, Matthias P. Ebert12, Nuh N. Rahbari12, Henrik E. Mei28, Axel Schulz28, Marc Ringelhan10, Nisar P. Malek, Stephan Spahn, Michael Bitzer, Marina Ruiz de Galarreta13, Amaia Lujambio13, Jean-François Dufour29, Thomas U. Marron30, Thomas U. Marron13, Ahmed Kaseb31, Masatoshi Kudo32, Yi Hsiang Huang33, Yi Hsiang Huang34, Nabil Djouder, Katharina Wolter7, Lars Zender2, Lars Zender7, Parice N. Marche35, Parice N. Marche36, Thomas Decaens36, Thomas Decaens35, David J. Pinato37, Roland Rad10, Roland Rad2, Joachim C. Mertens3, Achim Weber3, Kristian Unger, Felix Meissner11, Susanne Roth8, Zuzana Macek Jilkova36, Zuzana Macek Jilkova37, Zuzana Macek Jilkova35, Manfred Claassen7, Quentin M. Anstee5, Ido Amit9, Percy A. Knolle10, Burkhard Becher3, Josep M. Llovet13, Josep M. Llovet4, Josep M. Llovet38, Mathias Heikenwalder2 
15 Apr 2021-Nature
TL;DR: The progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers provides a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.
Abstract: Hepatocellular carcinoma (HCC) can have viral or non-viral causes1-5. Non-alcoholic steatohepatitis (NASH) is an important driver of HCC. Immunotherapy has been approved for treating HCC, but biomarker-based stratification of patients for optimal response to therapy is an unmet need6,7. Here we report the progressive accumulation of exhausted, unconventionally activated CD8+PD1+ T cells in NASH-affected livers. In preclinical models of NASH-induced HCC, therapeutic immunotherapy targeted at programmed death-1 (PD1) expanded activated CD8+PD1+ T cells within tumours but did not lead to tumour regression, which indicates that tumour immune surveillance was impaired. When given prophylactically, anti-PD1 treatment led to an increase in the incidence of NASH-HCC and in the number and size of tumour nodules, which correlated with increased hepatic CD8+PD1+CXCR6+, TOX+, and TNF+ T cells. The increase in HCC triggered by anti-PD1 treatment was prevented by depletion of CD8+ T cells or TNF neutralization, suggesting that CD8+ T cells help to induce NASH-HCC, rather than invigorating or executing immune surveillance. We found similar phenotypic and functional profiles in hepatic CD8+PD1+ T cells from humans with NAFLD or NASH. A meta-analysis of three randomized phase III clinical trials that tested inhibitors of PDL1 (programmed death-ligand 1) or PD1 in more than 1,600 patients with advanced HCC revealed that immune therapy did not improve survival in patients with non-viral HCC. In two additional cohorts, patients with NASH-driven HCC who received anti-PD1 or anti-PDL1 treatment showed reduced overall survival compared to patients with other aetiologies. Collectively, these data show that non-viral HCC, and particularly NASH-HCC, might be less responsive to immunotherapy, probably owing to NASH-related aberrant T cell activation causing tissue damage that leads to impaired immune surveillance. Our data provide a rationale for stratification of patients with HCC according to underlying aetiology in studies of immunotherapy as a primary or adjuvant treatment.

526 citations

Journal ArticleDOI
TL;DR: A rapid search in PubMed shows that using "flow cytometry immunology" as a search term yields more than 68 000 articles, the first of which is not about lymphocytes as mentioned in this paper.
Abstract: The marriage between immunology and cytometry is one of the most stable and productive in the recent history of science. A rapid search in PubMed shows that, as of July 2017, using “flow cytometry immunology” as a search term yields more than 68 000 articles, the first of which, interestingly, is not about lymphocytes. It might be stated that, after a short engagement, the exchange of the wedding rings between immunology and cytometry officially occurred when the idea to link fluorochromes to monoclonal antibodies came about. After this, recognizing different types of cells became relatively easy and feasible not only by using a simple fluorescence microscope, but also by a complex and sometimes esoteric instrument, the flow cytometer that is able to count hundreds of cells in a single second, and can provide repetitive results in a tireless manner. Given this, the possibility to analyse immune phenotypes in a variety of clinical conditions has changed the use of the flow cytometer, which was incidentally invented in the late 1960s to measure cellular DNA by using intercalating dyes, such as ethidium bromide. The epidemics of HIV/AIDS in the 1980s then gave a dramatic impulse to the technology of counting specific cells, since it became clear that the quantification of the number of peripheral blood CD4+ T cells was crucial to follow the course of the infection, and eventually for monitoring the therapy. As a consequence, the development of flow cytometers that had to be easy-to-use in all clinical laboratories helped to widely disseminate this technology. Nowadays, it is rare to find an immunological paper or read a conference abstract in which the authors did not use flow cytometry as the main tool to dissect the immune system and identify its fine and complex functions. Of note, recent developments have created the sophisticated technology of mass cytometry, which is able to simultaneously identify dozens of molecules at the single cell level and allows us to better understand the complexity and beauty of the immune system.

454 citations

Journal ArticleDOI
15 Feb 2005-Blood
TL;DR: The appearance of these plasma cells in the blood indicates successful competition for survival niches in the bone marrow between newly generated plasma blasts and resident plasma cells as a fundamental mechanism for the establishment of humoral memory and its plasticity.

433 citations


Cited by
More filters
28 Jul 2005
TL;DR: PfPMP1)与感染红细胞、树突状组胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作�ly.
Abstract: 抗原变异可使得多种致病微生物易于逃避宿主免疫应答。表达在感染红细胞表面的恶性疟原虫红细胞表面蛋白1(PfPMP1)与感染红细胞、内皮细胞、树突状细胞以及胎盘的单个或多个受体作用,在黏附及免疫逃避中起关键的作用。每个单倍体基因组var基因家族编码约60种成员,通过启动转录不同的var基因变异体为抗原变异提供了分子基础。

18,940 citations

01 Jan 2020
TL;DR: Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future.
Abstract: Summary Background Since December, 2019, Wuhan, China, has experienced an outbreak of coronavirus disease 2019 (COVID-19), caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Epidemiological and clinical characteristics of patients with COVID-19 have been reported but risk factors for mortality and a detailed clinical course of illness, including viral shedding, have not been well described. Methods In this retrospective, multicentre cohort study, we included all adult inpatients (≥18 years old) with laboratory-confirmed COVID-19 from Jinyintan Hospital and Wuhan Pulmonary Hospital (Wuhan, China) who had been discharged or had died by Jan 31, 2020. Demographic, clinical, treatment, and laboratory data, including serial samples for viral RNA detection, were extracted from electronic medical records and compared between survivors and non-survivors. We used univariable and multivariable logistic regression methods to explore the risk factors associated with in-hospital death. Findings 191 patients (135 from Jinyintan Hospital and 56 from Wuhan Pulmonary Hospital) were included in this study, of whom 137 were discharged and 54 died in hospital. 91 (48%) patients had a comorbidity, with hypertension being the most common (58 [30%] patients), followed by diabetes (36 [19%] patients) and coronary heart disease (15 [8%] patients). Multivariable regression showed increasing odds of in-hospital death associated with older age (odds ratio 1·10, 95% CI 1·03–1·17, per year increase; p=0·0043), higher Sequential Organ Failure Assessment (SOFA) score (5·65, 2·61–12·23; p Interpretation The potential risk factors of older age, high SOFA score, and d-dimer greater than 1 μg/mL could help clinicians to identify patients with poor prognosis at an early stage. Prolonged viral shedding provides the rationale for a strategy of isolation of infected patients and optimal antiviral interventions in the future. Funding Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences; National Science Grant for Distinguished Young Scholars; National Key Research and Development Program of China; The Beijing Science and Technology Project; and Major Projects of National Science and Technology on New Drug Creation and Development.

4,408 citations

Journal ArticleDOI
24 Jun 2021-Cell
TL;DR: Weighted-nearest neighbor analysis as mentioned in this paper is an unsupervised framework to learn the relative utility of each data type in each cell, enabling an integrative analysis of multiple modalities.

3,369 citations

Journal ArticleDOI
TL;DR: This review discusses recent progress and areas of uncertainty or disagreement in the literature, and debates the developmental relationship between T(FH) cells and other CD4 T cell subsets (Th1, Th2, Th17, iTreg).
Abstract: T cell help to B cells is a fundamental aspect of adaptive immunity and the generation of immunological memory. Follicular helper CD4 T (T(FH)) cells are the specialized providers of B cell help. T(FH) cells depend on expression of the master regulator transcription factor Bcl6. Distinguishing features of T(FH) cells are the expression of CXCR5, PD-1, SAP (SH2D1A), IL-21, and ICOS, among other molecules, and the absence of Blimp-1 (prdm1). T(FH) cells are important for the formation of germinal centers. Once germinal centers are formed, T(FH) cells are needed to maintain them and to regulate germinal center B cell differentiation into plasma cells and memory B cells. This review covers T(FH) differentiation, T(FH) functions, and human T(FH) cells, discussing recent progress and areas of uncertainty or disagreement in the literature, and it debates the developmental relationship between T(FH) cells and other CD4 T cell subsets (Th1, Th2, Th17, iTreg).

2,442 citations

Journal ArticleDOI
TL;DR: Recent studies addressing the multifaceted roles of FcRs for IgG (FcγRs) in the immune system are discussed and how this knowledge could be translated into novel therapeutic strategies to treat human autoimmune, infectious or malignant diseases are discussed.
Abstract: In addition to their role in binding antigen, antibodies can regulate immune responses through interacting with Fc receptors (FcRs). In recent years, significant progress has been made in understanding the mechanisms that regulate the activity of IgG antibodies in vivo. In this Review, we discuss recent studies addressing the multifaceted roles of FcRs for IgG (FcgammaRs) in the immune system and how this knowledge could be translated into novel therapeutic strategies to treat human autoimmune, infectious or malignant diseases.

2,390 citations